BeyondSpring Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing novel small-molecule therapies for oncology. Headquartered in Suzhou, China, with corporate operations in New York, the company leverages a versatile drug discovery platform to advance targeted treatments designed to improve outcomes for patients with cancer. BeyondSpring’s pipeline emphasizes agents that modulate the tumor microenvironment and enhance immune response, with an aim to address key unmet needs in supportive care and tumor control.
The company’s lead candidate, plinabulin, is a small-molecule vascular disrupting agent that also exhibits immunomodulatory activity. Plinabulin is being evaluated in multiple clinical trials for the prevention of chemotherapy-induced neutropenia and as a potential combination therapy in metastatic non-small cell lung cancer. BeyondSpring has secured Fast Track designation from the U.S. Food and Drug Administration for plinabulin’s use in neutropenia prevention, underscoring the agent’s differentiated mechanism of action and its potential to reduce chemotherapy-related complications.
BeyondSpring’s broader pipeline includes bezuclastinib, a selective tyrosine kinase inhibitor being studied for the treatment of advanced systemic mastocytosis and related disorders. This program highlights the company’s strategy of in-licensing or acquiring assets with first-in-class or best-in-class potential. BeyondSpring maintains research collaborations and conducts pharmacology and safety evaluations through its integrated facilities in Suzhou, as well as through partnerships with academic institutions and contract research organizations in North America and Europe.
Founded in 2010, BeyondSpring completed its initial public offering on the NASDAQ in 2019 under the ticker symbol BYSI. The company is led by President and Chief Executive Officer Mitchell Gold, alongside co-founder and Executive Chairman Dr. John Li, supported by a management team with extensive expertise in oncology drug development, regulatory affairs and global commercialization. BeyondSpring continues to advance its pipeline through late-stage clinical programs and regulatory filings, with the goal of bringing novel cancer therapeutics to patients worldwide.
AI Generated. May Contain Errors.
Free BYSI Stock Alerts